Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Transcranial Doppler in Preeclampsia and Its Complications. (DTC-PE)

9 november 2026 bijgewerkt door: Ben marzouk Sofiene, University Tunis El Manar

Diagnostic and Prognostic Value of Transcranial Doppler in Preeclampsia Impact of Maternal Comorbidities on Cerebral Hemodynamics

Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. It is defined by new-onset hypertension after 20 weeks of gestation, often associated with proteinuria and/or systemic complications such as thrombocytopenia, renal impairment, hepatic dysfunction, neurological symptoms, pulmonary edema, or intrauterine growth restriction. Neurological involvement is particularly severe, as it may progress to eclampsia, intracerebral hemorrhage, or ischemic stroke. Detecting early cerebral hemodynamic changes is therefore essential.

Transcranial Doppler (TCD) is a non-invasive ultrasound technique that measures cerebral blood flow velocities, particularly in the middle cerebral artery (MCA). It provides systolic, diastolic, and mean velocity values, and calculates indices such as pulsatility index (PI), resistance index (RI), cerebral perfusion pressure (CPP), resistance area product (RAP), cerebral flow index (CFI). These parameters can detect impaired cerebral autoregulation, . Although several studies suggest that preeclampsia is associated with altered cerebral hemodynamics, the diagnostic and prognostic role of TCD remains insufficiently defined.

The objective of this prospective, observational, case-control study is to evaluate the diagnostic and prognostic value of TCD in preeclampsia and its complications. The study will be conducted at the Maternity and Neonatology Center of Tunis (Departments of Anesthesia, Intensive Care, and Gynecology-Obstetrics A-D) over six months, from January to June 2025.

Participants will be pregnant women in their third trimester, divided into two groups:

  • Group A: preeclamptic women, defined by hypertension and proteinuria after 20 weeks of gestation, or hypertension/proteinuria with at least one severity criterion (hematologic, hepatic, renal, pulmonary, neurological, or fetal).
  • Group B: normotensive, non-preeclamptic controls.

Exclusion criteria include chronic hypertension, chronic kidney disease, epilepsy, hematologic disease, cardiac or liver disease, COPD, severe anemia, technical difficulties preventing TCD, loss to follow-up, or diagnostic uncertainty. Women with isolated gestational hypertension will also be excluded.

TCD will be performed via the temporal window using a 2 MHz pulsed Doppler probe, mainly focusing on the MCA. In Group A, measurements will be obtained before and after antihypertensive therapy, before and after magnesium sulfate administration when indicated . In Group B, a single TCD will be performed during the third trimester.

The study will compare cerebral blood flow velocities and indices between groups and monitor their evolution over time.

The expected outcome is to establish whether TCD can serve as a reliable diagnostic and prognostic tool in preeclampsia. The results will contribute to a better understanding of cerebrovascular physiology in this condition and may help identify women at higher risk of neurological or systemic complications. Ultimately, this work aims to highlight TCD as a simple, reproducible, and non-invasive tool for clinical management and risk stratification in preeclampsia.

Studie Overzicht

Toestand

Voltooid

Conditie

Gedetailleerde beschrijving

The study objectives and the procedures for performing transcranial Doppler (TCD) ultrasonography were explained to all patients who met the inclusion criteria. Only women who provided informed consent were included in the study.

Demographic characteristics and medical history were recorded for each patient using an individual pseudonymized data collection form. Physical examination findings, laboratory parameters, radiological investigation results, and transcranial Doppler (TCD) data were also collected .

For the TCD examination, patients were positioned in a slightly left lateral decubitus position, with a 15° tilt, and the head of the bed was elevated to 30°.

Transcranial Doppler ultrasonography was performed using a GE Venue Go R2 ultrasound system (GE Healthcare) equipped with a 2-MHz pulsed-wave Doppler probe. The probe was positioned over the temporal bone, above the zygomatic arch, between the ear tragus and the lateral canthus of the eye, to obtain the transtemporal acoustic window.

First, the midbrain peduncles, the cerebral falx, and the Sylvian fissure were identified using two-dimensional (2D) imaging.

The circle of Willis was then visualized using color Doppler, with particular attention to the middle cerebral artery (MCA). Its M1 segment typically displays an italic S-shaped course and is generally insonated at a depth of 45-65 mm.

The posterior cerebral artery (PCA) was explored using the internal carotid artery bifurcation as an anatomical landmark. The 2-MHz probe was progressively tilted and repositioned to identify the P1 and P2 segments, which are usually insonated at depths of approximately 60-70 mm and 70-80 mm, respectively.

Vessel identification was based on insonation depth, flow direction, and Doppler signal characteristics.

However, visualization of the PCA is not always feasible and may be limited or impossible in cases of inadequate temporal acoustic windows, anatomical variations, or technical difficulties. In such circumstances, the vessel was considered non-visualizable.

To minimize potential confounding factors that could influence cerebral hemodynamic parameters, TCD examinations were performed only in the absence of hyperthermia, hypoxia, hypoglycemia, or severe anemia (hemoglobin level >7 g/dL).

For each TCD examination, the following parameters were recorded for both the MCA and PCA:

  • Peak systolic velocity (PSV).
  • End-diastolic velocity (EDV).
  • Mean flow velocity (MFV).

Based on the collected clinical and Doppler data, the following cerebral hemodynamic parameters were calculated for each patient:

- Pulsatility index (PI), calculated using the following formula: IP= (Vs-Vd) / Vm

  • Resistance index (RI), calculated using the following formula:

IR= (Vs-Vd) / Vs

  • Estimated cerebral perfusion pressure (CPP), calculated using the following formula:

PPC =(Vm/(Vm-Vd)*(PAM-PAD)

  • Resistance Area Product (RAP), calculated using the following formula:

RAP = PAM /Vm

- Cerebral Flow Index (CFI), calculated using the following formula: CFI = PPC/ RAP Systolic, diastolic, and mean arterial blood pressure values were measured simultaneously with each Doppler assessment to allow calculation of these cerebral hemodynamic parameters.

Timing of TCD examinations:

In patients with preeclampsia, TCD examinations were performed at the following time points:

  1. Before initiation of antihypertensive treatment.

  2. After administration of antihypertensive treatment, when indicated, according to the following schedule:

    • 30 minutes after initiation of intravenous antihypertensive therapy.
    • Two hours after administration of oral antihypertensive therapy.
  3. Before magnesium sulfate administration, when indicated.

  4. Six hours after magnesium sulfate administration. In the control group, a single TCD examination was performed during the third trimester of pregnancy, using the same technical protocol.

4. Patient follow-up All patients were followed from the time of study inclusion until the first 48 hours postpartum.

During this period, maternal adverse events were systematically assessed and recorded.

The maternal complications investigated included:

  • Neurological complications: eclampsia, altered level of consciousness, focal neurological deficits, and neurosensory symptoms (headache, blurred vision, tinnitus, and brisk deep tendon reflexes).
  • Other clinical complications: acute pulmonary edema (APE) and oliguria.
  • Laboratory abnormalities: hemolytic anemia, elevated liver enzymes (hepatic cytolysis), thrombocytopenia suggestive of HELLP syndrome, and increased serum creatinine levels.
  • Radiological abnormalities: posterior reversible encephalopathy syndrome (PRES) or any other abnormalities detected on brain imaging, as well as subcapsular hepatic hematoma.

Statistical analysis The sample size was calculated using the method for comparing two means (independent-samples Student's t-test), considering the middle cerebral artery pulsatility index as the primary outcome measure, with a significance level (α) of 5% and a statistical power of 80%.

Statistical analyses were performed using SPSS® software, version 27.0.

Quantitative variables were expressed as mean ± standard deviation when normally distributed, and as median [first quartile; third quartile] otherwise. Normality of distributions was assessed using the Shapiro-Wilk test.

Qualitative variables were expressed as frequencies and percentages.

Quantitative variables were compared using Student's t-test or, in the case of non-n normally distributed data, the Mann-Whitney U test. Qualitative variables were compared using Pearson's chi-square test or Fisher's exact test when expected cell frequencies were below 5.

As age and body mass index (BMI) differed between the two groups, TCD parameters were compared after adjustment for these two variables using multiple linear regression (ANCOVA).

Associations between blood pressure and Doppler parameters were assessed using Spearman's rank correlation coefficient.

The diagnostic and prognostic performance of Doppler parameters was evaluated using receiver operating characteristic (ROC) curve analysis. The area under the curve (AUC) was calculated along with its 95% confidence interval (CI), obtained using the bootstrap method (2,000 resamples). The optimal cut-off value for each parameter was determined using Youden's index. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated at the corresponding cut-off value.

The AUCs of the best-performing parameters were compared using DeLong's test.

Changes in Doppler parameters before and after antihypertensive treatment, as well as before and after magnesium sulfate administration, were analyzed using the paired-samples Student's t-test.

Changes in each parameter (post-treatment value - baseline value) were compared between patients receiving nicardipine alone and those receiving combination therapy using Student's t-test.

These changes were subsequently compared using linear regression, adjusted for the baseline value of the corresponding parameter, to account for confounding by indication and regression to the mean.

Correlations between changes in Doppler parameters and changes in mean arterial pressure (MAP) were assessed using Spearman's rank correlation coefficient.

Statistical significance was set at p < 0.05 for all tests, using two-sided testing.

Ethical considerations:

The study was conducted after obtaining approval from the local ethics committee (Approval No. 06/2025) and written informed consent from all participating patients

All patients who met the inclusion criteria were fully informed about the study protocol and its procedures.

The authors declare no conflicts of interest. Medical confidentiality, patient anonymity, and the protection of personal data were ensured throughout the study.

The study was registered on ClinicalTrials.gov (NCT07646561) Literature search:

The literature search was conducted using the following databases and search engines: BioMed Central, ScienceDirect, SpringerLink, Web of Science, and Google Scholar.

References were managed using Zotero® software, version 27 (https://www.zotero.org), and formatted according to the Vancouver referencing style.

Studietype

Observationeel

Inschrijving (Werkelijk)

98

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Tunis, Tunesië
        • Tunis maternity and neonatology center, ministery of public health, Tunis ,1007

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 45 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Vrouw

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Pregnant women in their third trimester (28 weeks or more) participating in this study are divided into two groups:

  • Group A: Women diagnosed with preeclampsia according to standard clinical and laboratory criteria, including elevated blood pressure and proteinuria, with or without severe features.
  • Group B: Healthy, normotensive pregnant women without signs of preeclampsia. Participants are included after providing informed consent and are monitored for cerebral blood flow parameters using transcranial Doppler ultrasound.

Beschrijving

Inclusion Criteria:

  • Consenting pregnant women in their third trimester (28 weeks of gestation or more)
  • Group A: Patients with preeclampsia, defined as:
  • Systolic Blood Pressure (SBP) equal to or greater than 140 mmHg and/or Diastolic Blood Pressure (DBP) equal to or greater than 90 mmHg appearing after 20 weeks of gestation with 24-hour proteinuria equal to or greater than 300 mg/24h, or
  • SBP equal to or greater than 140 mmHg and/or DBP equal to or greater than 90 mmHg or 24-hour proteinuria equal to or greater than 300 mg/24h with at least one of the following
  • Thrombocytopenia, platelets below 100,000 per cubic millimeter
  • Liver cytolysis, AST or ALT more than 2 times normal values
  • Hemolytic anemia (schistocytes present, LDH above 600)
  • Serum creatinine equal to or greater than 90 micromoles per liter and oliguria equal to or less than 500 milliliters per 24 hours, excluding functional or obstructive causes
  • Acute pulmonary edema
  • Subcapsular liver hematoma
  • Neurological or sensory signs (headache, blurred vision, tinnitus, hyperreflexia, diffuse polykinetic reflexes)
  • Eclampsia
  • Severe intrauterine growth restriction
  • Group B: Healthy, normotensive pregnant women
  • SBP less than 140 mmHg and DBP less than 90 mmHg
  • No clinical or biological signs of severe preeclampsia
  • Negative 24-hour proteinuria test, less than 300 mg/24h, if performed

Exclusion Criteria:

  • Multiple pregnancy (twins, triplets, etc.)
  • History of significant neurological or cardiovascular disease
  • Active infection or major medical complication
  • Allergy or contraindication to antihypertensive therapy or magnesium sulfate
  • Refusal to provide informed consent

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
• Group A: Pregnant women with preeclampsia in the third trimester

• Group A: patients with pre eclampsia, defined as follows: Patients with Systolic Blood Pressure greater or equal than140 mmHg and or Diastolic Blood Pressure greater or equal than 90 mmHg appearing after 20 weeks of gestation, WITH the presence of 24hour proteinuria greater or equal than300 mg per 24h, OR Patients with SBP greater or equal140 mmHg and or DBP greater or equal than 90 mmHg or 24hour proteinuria greater or equal than 300 mg per24h, WITH at least one of the following criteria Thrombocytopenia less than 100,000 permm³ Liver cytolysis greater than 2 times normal values Hemolytic anemia schistocytes, LDH more than 600 Serum creatinine mo 90 µmol per L and oliguria less or equal than500 ml per 24h excluding any functional or obstructive cause Acute pulmonary edema Subcapsular liver hematoma Neurological or sensory signs Eclampsia Severe intrauterine growth restriction

Group B: Non-Preeclamptic Normotensive Patients

Patients with SBP less than 140 mmHg and DBP less than 90 mmHg, with no clinical or biological abnormalities suggesting severe preeclampsia, and a negative 24hour proteinuria test if performed.

This intervention involves performing Transcranial Doppler (TCD) ultrasound on pregnant women with preeclampsia in the third trimester. TCD is a non-invasive imaging technique used to assess cerebral blood flow velocity and detect potential cerebrovascular complications. The procedure is performed at the bedside, using standard clinical protocols. No contrast agents or medications are administered. This intervention is distinct from other ultrasound procedures as it specifically targets intracranial arteries and provides real-time hemodynamic data relevant to preeclampsia.

Andere namen:
  • TCD
  • Doppler-echografie

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To assess the diagnostic value of the pulsatility index (PI) measured in the middle cerebral artery (MCA) using transcranial Doppler (TCD) ultrasonography in preeclampsia.
Tijdsspanne: Measured during the third trimester

pulsatility index (PI) will be measured in the MCA using transcranial Doppler ultrasound in pregnant women with preeclampsia and in healthy pregnant women. The study aims to evaluate the diagnostic value of this parameter: for women with preeclampsia, to identify severe forms of the disease, and for healthy pregnant women, to assess the risk of developing preeclampsia after the Doppler measurement.

Measured during the third trimester

Secundaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
- To assess the diagnostic value of other TCD parameters measured in the MCA (Vs, Vm, Vd, RI, CPP, IFC, RAP) and the posterior cerebral artery (PCA) (Vs, Vm, Vd, PI, RI, CPP, IFC, RAP) in preeclampsia
Tijdsspanne: Measured during the third trimester
Measured during the third trimester
To investigate the relationship between TCD parameters and the severity of preeclampsia
Tijdsspanne: at study enrollement
at study enrollement
To investigate the relationship between TCD parameters and blood pressure levels in preeclampsia;
Tijdsspanne: at study enrollement
at study enrollement
To assess changes in TCD parameters following antihypertensive treatment and magnesium sulfate administration in preeclampsia;
Tijdsspanne: at study enrollement
at study enrollement
To evaluate the prognostic value of TCD in predicting the severity of preeclampsia and the occurrence of neurological manifestations.
Tijdsspanne: at study enrollement
at study enrollement

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 januari 2025

Primaire voltooiing (Werkelijk)

30 juni 2025

Studie voltooiing (Werkelijk)

31 juli 2025

Studieregistratiedata

Eerst ingediend

31 augustus 2025

Eerst ingediend dat voldeed aan de QC-criteria

9 juni 2026

Eerst geplaatst (Werkelijk)

12 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren